...
首页> 外文期刊>Journal of Medicinal Chemistry >Identification of Putative Agouti-Related Protein(87-132)-Melanocortin-4 Receptor Interactions by Homology Molecular Modeling and Validation Using Chimeric Peptide Ligands
【24h】

Identification of Putative Agouti-Related Protein(87-132)-Melanocortin-4 Receptor Interactions by Homology Molecular Modeling and Validation Using Chimeric Peptide Ligands

机译:通过同源性分子建模和嵌合肽配体的验证,确定推定的刺痛相关蛋白(87-132)-Melanocortin-4受体相互作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Agouti-related protein (AGRP) is one of only two naturally known antagonists of G-protein-coupled receptors (GPCRs) identified to date. Specifically, AGRP antagonizes the brain melanocortin-3 and -4 receptors involved in energy homeostasis. α-Melanocyte stimulating hormone (α-MSH) is one of the known endogenous agonists for these melanocortin receptors. Insight into putative interactions between the antagonist AGRP amino acids with the melanocortin-4 receptor (MC4R) may be important for the design of unique ligands for the treatment of obesity related diseases and is currently lacking in the literature. A three-dimensional homology molecular model of the mouse MC4 receptor complex with the hAGRP(87-132) ligand docked into the receptor has been developed to identify putative antagonist ligand-receptor interactions. Key putative AGRP-MC4R interactions include the Arg111 of hAGRP(87-132) interacting in a negatively charged pocket located in a cavity formed by transmembrane spanning (TM) helices 1, 2, 3, and 7, capped by the acidic first extracellular loop (EL1) and specifically with the conserved melanocortin receptor residues mMC4R Glu92 (TM2), mMC4R Asp114 (TM3), and mMC4R Asp118 (TM3). Additionally, Phe112 and Phe113 of hAGRP(87-132) putatively interact with an aromatic hydrophobic pocket formed by the mMC4 receptor residues Phe176 (TM4), Phe193 (TM5), Phe253 (TM6), and Phe254 (TM6). To validate the AGRP-mMC4R model complex presented herein from a ligand perspective, we generated nine chimeric peptide ligands based on a modified antagonist template of the hAGRP(109-118) (Tyr-c[Asp-Arg-Phe-Phe-Asn-Ala-Phe-Dpr]-Tyr-NH_2). In these chimeric ligands, the antagonist AGRP Arg-Phe-Phe residues were replaced by the melanocortin agonist His/D-Phe-Arg-Trp amino acids. These peptides resulted in agonist activity at the mouse melanocortin receptors (mMC1R and mMC3-5Rs). The most notable results include the identification of a novel subnanomolar melanocortin peptide template Tyr-c[Asp-His-DPhe-Arg-Trp-Asn-Ala-Phe-Dpr]-Tyr-NH_2 that is equipotent to α-MSH at the mMC1, mMC3, and mMC5 receptors but is 30-fold more potent than -MSH at the mMC4R. Additionally, these studies identified a new and novel >200-fold MC4R versus MC3R selective peptide Tyr-c[Asp-D-Phe-Arg-Trp-Asn-Ala-Phe-Dpr]-Tyr-NH2 template. Furthermore, when the His-DPhe-Arg-Trp sequence is used to replace the hAGRP Arg-Phe-Phe residues in the "mini"-AGRP (hAGRP87-120, C105A) template, a potent nanomolar agonist resulted at the mMC1R and MC3-5Rs.
机译:刺痛相关蛋白(AGRP)是迄今确定的仅有的两种自然已知的G蛋白偶联受体(GPCR)拮抗剂之一。具体而言,AGRP拮抗参与能量稳态的大脑黑素皮质素3和-4受体。 α-黑素细胞刺激激素(α-MSH)是这些黑皮质素受体的已知内源性激动剂之一。了解拮抗剂AGRP氨基酸与黑皮质素4受体(MC4R)之间的假定相互作用可能对于设计用于治疗肥胖症相关疾病的独特配体很重要,目前尚缺乏文献报道。已经建立了小鼠MC4受体复合物与停靠在该受体中的hAGRP(87-132)配体的三维同源性分子模型,以鉴定推定的拮抗剂配体-受体相互作用。关键的假定AGRP-MC4R相互作用包括hAGRP(87-132)的Arg111在带负电荷的口袋中相互作用,该口袋位于由跨膜跨膜(TM)螺旋1、2、3和7形成的空腔中,该空腔被酸性的第一个细胞外环覆盖(EL1),特别是带有保守的黑皮质素受体残基的mMC4R Glu92(TM2),mMC4R Asp114(TM3)和mMC4R Asp118(TM3)。此外,hAGRP(87-132)的Phe112和Phe113可能与由mMC4受体残基Phe176(TM4),Phe193(TM5),Phe253(TM6)和Phe254(TM6)形成的芳香疏水口袋相互作用。为了从配体的角度验证本文介绍的AGRP-mMC4R模型复合物,我们基于hAGRP(109-118)(Tyr-c [Asp-Arg-Phe-Phe-Asn- Ala-Phe-Dpr] -Tyr-NH_2)。在这些嵌合配体中,拮抗剂AGRP Arg-Phe-Phe残基被黑皮质素激动剂His / D-Phe-Arg-Trp氨基酸取代。这些肽对小鼠黑皮质素受体(mMC1R和mMC3-5Rs)产生激动剂活性。最值得注意的结果包括鉴定了在mMC1上与α-MSH等价的新型亚纳摩尔黑皮质素肽模板Tyr-c [Asp-His-DPhe-Arg-Trp-Asn-Ala-Phe-Dpr] -Tyr-NH_2 ,mMC3和mMC5受体,但在mMC4R处的效力比-MSH高30倍。此外,这些研究还确定了新的和新颖的> 200倍的MC4R与MC3R选择性肽Tyr-c [Asp-D-Phe-Arg-Trp-Asn-Ala-Phe-Dpr] -Tyr-NH2模板。此外,当使用His-DPhe-Arg-Trp序列替换“ mini” -AGRP(hAGRP87-120,C105A)模板中的hAGRP Arg-Phe-Phe残基时,在mMC1R和MC3处产生了强大的纳摩尔激动剂-5卢比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号